MedTrace Logo

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

NCT01662102 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-10-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of consolidation treatment Zevalin® versus maintenance treatment with Rituxan® on progression-free survival (PFS) following response induction with chemotherapy plus rituximab in previously untreated participants with follicular lymphoma.

Conditions

Interventions

DRUG

Zevalin

Zevalin administered intravenously.

DRUG

Rituximab

Rituximab administered intravenously.

Sponsors & Collaborators

  • Spectrum Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Fernando Cabanillas, MD · M.D. Anderson Cancer Center

  • Thomas Witzig, MD · The Mayo Clinic & Foundation

  • Steven E Finkelstein, MD · GenesisCare USA

  • Leonard Klein, MD · Illinois Cancer Specialists - US Oncology

  • Steven Jubelirer, MD · West Virginia University

  • Petros Nikolinakos, MD · Northeast Georgia Cancer Care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-11
Primary Completion
2013-03-05
Completion
2013-03-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01662102 on ClinicalTrials.gov